Ardelyx, Inc.
ARDXArdelyx, Inc. (ARDX) is a biotechnology company focused on developing and commercializing novel treatments for cardio-renal and gastrointestinal diseases. Founded to address unmet medical needs, Ardelyx's portfolio includes therapies targeting conditions such as chronic kidney disease, constipation, and other gastrointestinal disorders.
Company News
Cable One reported disappointing Q1 2025 earnings, missing analyst expectations and suspending its dividend. The stock price fell over 40% on this news, leading Pomerantz LLP to investigate potential securities fraud or other unlawful business practices by the company and its officers/directors.
Ardelyx, a biopharmaceutical company, announced that it will present data supporting its product IBSRELA (tenapanor) at the Digestive Disease Week 2025 Conference.
Ardelyx, a biopharmaceutical company, announced that it will present data on its IBS-C drug IBSRELA and results from the IBS in America 2024 survey at the upcoming Digestive Disease Week Conference.
Ardelyx, a biopharmaceutical company, announced that it will present at the TD Cowen's 45th Annual Health Care Conference on March 3, 2025. The company has two commercial products approved in the U.S. and has agreements for the development and commercialization of its product tenapanor outside the U.S.
Ardelyx, a biopharmaceutical company, announced that its President and CEO, Mike Raab, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.
